R
4.10
-0.08 (-1.91%)
| Penutupan Terdahulu | 4.18 |
| Buka | 4.21 |
| Jumlah Dagangan | 23,333,506 |
| Purata Dagangan (3B) | 23,958,413 |
| Modal Pasaran | 2,137,177,216 |
| Harga / Jualan (P/S) | 38.57 |
| Harga / Buku (P/B) | 2.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -1,297.85% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.95% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -388.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -204.88 M |
| Pulangan Atas Aset (ROA TTM) | -38.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -86.10% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Recursion Pharmaceuticals, Inc. | Menaik | Bercampur |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.38 |
|
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.78% |
| % Dimiliki oleh Institusi | 69.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kinnevik Ab (Publ) | 30 Sep 2025 | 13,434,171 |
| Mic Capital Management Uk Llp | 30 Sep 2025 | 9,644,032 |
| Data Collective Iv Gp, Llc | 30 Sep 2025 | 5,941,120 |
| Julat 52 Minggu | ||
| Median | 11.00 (168.29%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 17 Dec 2025 | 11.00 (168.29%) | Beli | 4.68 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |